The Disaster that MyCite was and the inept Otsuka leadership

Discussion in 'Otsuka' started by anonymous, Dec 27, 2020 at 8:44 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I can't believe that Otsuka bought Proteus' lame and useless technology. Another sign of how dumb and inept Otsuka's leadership is. Otsuka will NEVER be a digital health company. It has failed not only with MyCite but also with Mentat. Mentat was more vaporware when it came to AI and the leadership and team behind that POS were absolutely clueless.

    Kabir, if your brain is still fully functioning then the following statement is something you should pay attention to --> “I think the key issue here is ‘So what? So, you have a cool technology. A cool technology by itself does not make a successful business.'" said industry analyst David Shaywitz, M.D., founder of advisory services firm Astounding HealthTech. "The lesson here is—what problem are you trying to solve?"

    The problem Otsuka was trying to solve was not for patients or health in general but how internal inept senior leaders could get promoted and stay employed. MyCite and Mentat were nothing but internal job opportunities and nothing more. To think that Kabir's decision to buy Proteus' technology was a smart deal is the very reason Otsuka is at the bottom of the pile within the industry. Japan is asleep at the wheel yet again.
     

  2. anonymous

    anonymous Guest

    Come on... US leadership would have been silly to let $15m get in the way of appearing less persistent in front of the Japan.
    A 2019 BMJ study said “there was no evidence of better adherence with the digital version of aripiprazole compared with the non-digital version.”
    MyCite could have probably been a nice wraparound to help stave off generics (if given free) but it isn’t likely to amount to much without being able to justify the added cost (starting with proof of improving adherence).
     
  3. anonymous

    anonymous Guest

    Yes, but you know what? As long as Otsuka can charge what it does for crappy Rexulti, the money comes in, everybody gets paid astronomically for accomplishing very little, and the show goes on! I hope Trump’s 4 initiatives to lower drug prices will eliminate the huge waste and redundancy in our industry. In no other industry would our leadership make it.
     
  4. anonymous

    anonymous Guest

    Whaaat? You are dogging the Big Rexulti? You obviously are not using your patient profiles enough. Yeah, I guess you could say it’s a me-too drug, but it’s OUR me-too drug! Can’t wait to get back into offices and hit the Big R hard!
     
  5. anonymous

    anonymous Guest

    Oh yes, Mr Trump....illusions are just part of your narcisistic personality....
     
  6. anonymous

    anonymous Guest

    "Really"..!!?? Are you a high school dropout hired by Otsuka?
     
  7. anonymous

    anonymous Guest

    I think the person you are responding to is making what is called a “joke”, you pathetic dumb piece of shit.
     
  8. anonymous

    anonymous Guest

    Waste of money....no faith in the CIO to use the technology wisely
     
  9. anonymous

    anonymous Guest

    The CIO, in any company, should never be let near anything patient facing. The real incompetence is the digital health lead, who has a poor work history. MyCite was an embarrassment but more importantly it was a clear sign to the organization that the company culture is all about ripping off patients and the government. There was never an effort to improve patient lives just an effort to keep jobs by working on a multiyear project with BS data. In the end reality bubbled up and the market said loudly they thought our digital health products are shit. The money could have gone to other more worthwhile ideas but we have idiots with delusions of grandeur at the board level.
     
  10. anonymous

    anonymous Guest

    Couldn't have said it better. But that is the culture at Otsuka!!!
     
  11. anonymous

    anonymous Guest

    Delusional Innovation is what we do best.